1697 completed. 1697 Phase 1, 491 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1697 | Completed 1697 |
| Phase 2 | 491 | Completed 491 |
Follow Lymphatic Diseases: new trials by email Literature Review of Lymphatic Diseases trials Research Report on Lymphatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) DZD8586 - Lymphoma, Non-Hodgkin | Phase 1 | Completed | Dizal Pharmaceuticals | 6 | 2026-03-16 | 2026-05-14 |
| A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia 14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias | Phase 1 | Completed | Janssen Research & Development, LLC | 6 | 2025-11-18 | 2026-09-25 |
| Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) Opemalirsen (AZD2373) - Renal Impairment | Phase 1 | Completed | AstraZeneca | 35 | 2025-08-18 | 2026-06-26 |
| A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma WTX-330 - Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Werewolf Therapeutics, Inc. | 24 | 2025-04-21 | 2026-10-19 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 AZD2389 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 35 | 2025-02-04 | 2025-09-24 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment BMS-986369 - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Celgene | 29 | 2024-08-15 | 2026-01-23 |
| A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies CTX131 - T Cell Lymphoma, B Cell Lymphoma | Phase 1 | Completed | CRISPR Therapeutics | 12 | 2024-08-13 | 2026-11-05 |
| Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment BMS-986278 - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 37 | 2024-06-10 | 2025-01-22 |
| Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya Artesunate pessary, blood draws for pharmacokinetics of the study drug - Cervix Cancer, Cervix Intraepithelial Neoplasia Grade 3 | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 12 | 2024-05-29 | 2025-08-19 |
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 104 | 2024-05-21 | 2025-12-05 |
| A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment Repotrectinib - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Bristol-Myers Squibb | 18 | 2024-04-29 | 2025-10-06 |
| A Study of PD5K3 in Healthy Adult Volunteers PD5K3, Placebo, Pegaspargase - Lymphoblastic Leukemia, Acute, Lymphoblastic Lymphoma | Phase 1 | Completed | Chongqing Peg-Bio Biopharm Co., Ltd. | 28 | 2023-11-27 | 2024-07-30 |
| FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) FT522, Rituximab, Cyclophosphamide - Relapsed/Refractory B-Cell Lymphoma | Phase 1 | Completed | Fate Therapeutics | 20 | 2023-11-16 | 2025-08-22 |
| A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers [14C]SHR2554 - Lymphoma | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 6 | 2023-10-07 | 2024-02-01 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator - Epstein-Barr Virus Infection, Infectious Mononucleosis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 2023-09-22 | 2026-04-22 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia anti-CD19 CAR T-cells - B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 18 | 2023-08-02 | 2025-08-26 |
| A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China Maplirpacept - Non-Hodgkin Lymphoma, Multiple Myeloma | Phase 1 | Completed | Pfizer | 10 | 2023-06-28 | 2024-11-20 |
| A Food Effect Study of LP-168 Tablets in Healthy Subjects LP-168 tablet - Mantle Cell Lymphoma | Phase 1 | Completed | Guangzhou Lupeng Pharmaceutical Company LTD. | 22 | 2023-06-21 | 2023-09-11 |
Showing 20 of 1697. Sign in to see all of them.
Lymphoma (582) · Lymphoma, Non-Hodgkin (493) · Leukemia, Lymphocytic, Chronic, B-Cell (444) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (434) · Lymphoma, Follicular (338) · Lymphoma, Large B-Cell, Diffuse (333) · Lymphoma, Mantle-Cell (295) · Hodgkin Disease (283) · Leukemia (278) · Leukemia, Myeloid, Acute (248) · Lymphoma, B-Cell, Marginal Zone (222) · Burkitt Lymphoma (215) · Multiple Myeloma (179) · Neoplasms (157) · Lymphoma, Large-Cell, Immunoblastic (153)
Hemic and Lymphatic Diseases (1697) · Immune System Diseases (1646) · Neoplasms by Histologic Type (1637) · Immunoproliferative Disorders (1633) · Lymphoproliferative Disorders (1620) · Neoplasms (1493) · Hematologic Diseases (890) · Leukemia, Lymphoid (729) · Lymphoma (690) · Pathological Conditions, Signs and Symptoms (684) · Pathologic Processes (680) · Disease Attributes (639) · Chronic Disease (544) · Leukemia (540)
Rituximab (180) · Cyclophosphamide (144) · Etoposide (78) · fludarabine phosphate (78) · Vincristine (74) · Cytarabine (70) · fludarabine (68) · Lenalidomide (63) · Doxorubicin (62) · Filgrastim (62) · Bendamustine Hydrochloride (57) · Bortezomib (53) · Prednisone (51) · Peripheral Blood Stem Cell Transplantation (49) · Dexamethasone (48)
National Cancer Institute (NCI) (178) · M.D. Anderson Cancer Center (66) · Memorial Sloan Kettering Cancer Center (36) · Fred Hutchinson Cancer Center (32) · Celgene (28) · Hoffmann-La Roche (24) · Novartis Pharmaceuticals (23) · City of Hope Medical Center (19) · Millennium Pharmaceuticals, Inc. (19) · Mayo Clinic (17) · Seagen Inc. (17) · AbbVie (15) · Dana-Farber Cancer Institute (15) · Genentech, Inc. (15) · Merck Sharp & Dohme LLC (15)
United States (1319) · France (117) · United Kingdom (117) · Canada (112) · Germany (94) · Australia (79) · Spain (73) · China (72) · Italy (69) · Japan (50) · South Korea (47) · Netherlands (40) · Poland (30) · Belgium (29) · Switzerland (27)
Brenda Sandmaier (6)
PMID 34515338, PMID 32499241, PMID 32770353, PMID 33883258, PMID 34398557, PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 19238148, PMID 20236866, PMID 32705923, PMID 34687939, PMID 34780125, PMID 37486616, PMID 37981564, PMID 39813680, PMID 15100156, PMID 17284531, PMID 19451441, PMID 19949018, PMID 20028764, PMID 20188202, PMID 20882050, PMID 21816833, PMID 22002018, PMID 22510871, PMID 23607606, PMID 23886836, PMID 24055823, PMID 24265828, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26659915, PMID 26813675, PMID 27482888, PMID 28314699, PMID 30262660, PMID 31023700, PMID 31050355, PMID 31355467, PMID 32508818, PMID 32596842, PMID 33051668, PMID 33308471, PMID 34310745, PMID 34321836, PMID 34493319, PMID 36813886
P30CA015704 (19), 2015 (18), 2016 (17), P30CA006973 (12), P30CA016672 (12), P30CA033572 (12), U01CA070095 (12), U01CA097452 (12), 2014 (11), U01CA076576 (11), 2017 (10), U01CA062502 (10), 2009 (9), U01CA062461 (9), U01CA062505 (9)